The Motley Fool on MSN17h
Is Viking Therepautics a Buy Now?
Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
Viking Therapeutics participates in a conference call with JPMorgan
Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Why Viking Therapeutics Stock Plummeted After Soaring Today
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Hosted on MSN1d
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat
Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...
Viking Therapeutics price target raised to $102 from $90 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Viking Therapeutics (VKTX) to $102 from $90 and keeps a Buy rating on the shares. The ...